Exo Imaging

Executive Summary

Exo Imaging is a privately held medical technology company based in Santa Clara, CA, that has developed an integrated point-of-care ultrasound (POCUS) ecosystem. Its flagship product, the Iris ultrasound device, combines high-performance portable hardware with a suite of AI-powered software tools for real-time image guidance, automated measurements, and workflow optimization. The platform aims to democratize ultrasound by making it faster, easier, and more accessible across diverse clinical settings, from emergency departments to primary care. Founded in 2015, Exo has raised significant venture capital to date and is positioning itself as a leader in the AI-enhanced POCUS market. The global POCUS market is expanding rapidly, driven by the need for cost-effective, portable diagnostics and the integration of artificial intelligence. Exo's competitive edge lies in its end-to-end ecosystem—hardware, AI, and cloud-based workflow management—which differentiates it from traditional ultrasound vendors and emerging software-only players. With a strong intellectual property portfolio and a seasoned leadership team, the company is well-positioned for growth. Near-term catalysts include potential FDA clearances for new AI applications, strategic distribution partnerships, and an upcoming funding round to scale commercialization. We assign a conviction score of 75 out of 100 based on the company's innovative platform and clear market tailwinds.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for AI-powered automated measurement algorithms70% success
• Q3 2026Strategic partnership with a major U.S. hospital network for large-scale deployment60% success
• Q2 2026Closing of Series D funding round to accelerate commercial expansion50% success